Date: 2017-06-26
Type of information: Grant
Company: BerGenBio (Norway)
Investors: Innovasjon Norge (Norway)
Amount: NOK 24 million ($2.85m)
Funding type: grant
Planned used:
- This grant will upport the clinical development of BGB324 in combination with Merck & Co.’s Keytruda® (pembrolizumab) in patients with advanced lung cancer. BerGenBio will sponsor a Phase II study multi-centre study of BGB324 in combination with Keytruda® in patients with previously treated unresectable adenocarcinoma of the lung.
- In March 2017, BerGenBio entered into a collaborative agreement with Merck & Co.focused on the clinical evaluation of BGB324 with Keytruda® in patients with advanced non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).
Others:
- • On June 26 2017, BerGenBio announced the award of a NOK 24 million ($2.85m) grant from Innovasjon Norge to support the clinical development of BGB324 in combination with Merck & Co.’s Keytruda® (pembrolizumab) in patients with advanced lung cancer.
- The grant from Innovasjon Norge is an Industrial Development Award (IFU). The IFU program is directed to Norwegian companies developing new products or services in collaboration with foreign companies. The NOK 24 million grant will contribute towards BerGenBio’s costs of running this specific Phase II clinical trial.
Therapeutic area: Cancer - Oncology
Is general: Yes
